​

Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

CATX Stock Forecast

Perspective Therapeutics (CATX) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $14.00 and a low of $14.00. This represents a 351.61% increase from the last price of $3.10.

- $4 $8 $12 $16 $20 High: $14 Avg: $14 Low: $14 Last Closed Price: $3.1

CATX Stock Rating

Perspective Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

CATX Price Target Upside V Benchmarks

TypeNameUpside
StockPerspective Therapeutics351.61%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks18.84%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$14.00$14.00$14.00
Last Closing Price$3.10$3.10$3.10
Upside/Downside351.61%351.61%351.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 253101--14
Sep, 253101--14
Aug, 253101--14
Jul, 253101--14
Jun, 253101--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 10, 2025Jeet MukherjeeBTIG$14.00$4.20233.33%351.61%
Oct 24, 2024David DaiUBS$20.00$11.6971.09%545.16%
Oct 14, 2024Jeff JonesOppenheimer$22.00$12.6673.78%609.68%
Sep 25, 2024Nicole GerminoTruist Financial$21.00$12.2871.01%577.42%
Jul 25, 2024Alec StranahanBank of America Securities$24.00$12.8287.21%674.19%
Jun 18, 2024Jeff JonesOppenheimer$19.00$11.9359.26%512.90%
Jun 14, 2024Gregory RenzaRBC Capital$3.00$1.15160.87%-3.23%
May 15, 2024Jeff JonesOppenheimer$2.00$1.5727.39%-35.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2025BTIGBuyinitialise
Sep 15, 2025OppenheimerOutperformOutperformhold
Jun 23, 2025B. RileyBuyBuyhold
Mar 07, 2025ScotiabankOutperforminitialise
Oct 24, 2024UBSBuyinitialise
Oct 14, 2024OppenheimerOutperformOutperformhold
Sep 30, 2024WedbushOutperforminitialise
Jun 18, 2024OppenheimerOutperformOutperformhold
Jun 14, 2024RBC CapitalOutperformOutperformhold
May 15, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported--$-0.10$-1.40-
Avg Forecast$-0.43$-0.27$-0.14$-1.30$-1.20
High Forecast$-0.43$-0.27$-0.12$-1.26$-0.99
Low Forecast$-0.43$-0.27$-0.16$-1.37$-1.85
Surprise %---28.57%7.69%-

Revenue Forecast

$0 $3M $6M $9M $12M $15M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported--$7.10M$1.43M-
Avg Forecast$10.10M$10.03M$8.46M$7.86M$12.81M
High Forecast$10.10M$10.03M$8.90M$10.48M$12.81M
Low Forecast$10.10M$10.03M$8.02M$6.39M$12.81M
Surprise %---16.03%-81.76%-

Net Income Forecast

$-65M $-52M $-39M $-26M $-13M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported--$-14.67M$-46.51M-
Avg Forecast$-61.58M$-37.89M$-3.75M$-35.19M$-32.12M
High Forecast$-61.58M$-37.89M$-3.21M$-33.61M$-26.50M
Low Forecast$-61.58M$-37.89M$-4.28M$-36.77M$-49.51M
Surprise %--291.51%32.17%-

CATX Forecast FAQ

Is Perspective Therapeutics stock a buy?

Perspective Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Perspective Therapeutics is a favorable investment for most analysts.

What is Perspective Therapeutics's price target?

Perspective Therapeutics's price target, set by 10 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $14 at the low end to $14 at the high end, suggesting a potential 351.61% change from the previous closing price of $3.1.

How does Perspective Therapeutics stock forecast compare to its benchmarks?

Perspective Therapeutics's stock forecast shows a 351.61% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (18.84%).

What is the breakdown of analyst ratings for Perspective Therapeutics over the past three months?

  • October 2025: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.

What is Perspective Therapeutics’s EPS forecast?

Perspective Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.2, marking a -14.29% decrease from the reported $-1.4 in 2023..

What is Perspective Therapeutics’s revenue forecast?

Perspective Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $12.81M, reflecting a 793.31% increase from the reported $1.43M in 2023.

What is Perspective Therapeutics’s net income forecast?

Perspective Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-32.117M, representing a -30.94% decrease from the reported $-46.508M in 2023.